Dougherty et al. found [19] the same BRAF V600E mutation in 9 of 18 pure pediatric GGs in their larger tumor cohort, none of which had a more adverse clinical outcome compared to non-mutated pediatric GGs, although the 3-year-follow-up time was short and not complete for the entire group. The gene discussed is BRAF; the disease is neoplasm.